BIO 2011 special report: The third wave of Australian biotechs
15 June, 2011 by Tim DeanFollowing the successes of the last six months in Australian biotechnology, the question becomes: who’s next?
BIO 2011 special report: Australian biotechnology comes of age
14 June, 2011 by Tim DeanThe Australian biotechnology industry has entered a new phase, with several high profile deals demonstrating the sector can truly deliver. Now attention is turning to what comes next.
Bluechiip to list on ASX tomorrow
08 June, 2011 by Tim DeanWireless tracking and sensor company Bluechiip will list on the ASX on Thursday 9 June 2011 after several months winding up to the big day.
Otifex lands $1.1m to develop treatment for childhood hearing problems
07 June, 2011 by Staff WritersMelbourne-based biotech plans to develop a nasal spray to treat otitis media with effusion (OME).
Stem cell breakthrough offers hope for treating kidney disease
18 May, 2011 by Tim DeanAustralian scientists have generated induced pluripotent stem cells from adult differentiated kidney cells, opening up the possibility of better understanding and treatment of kidney disease.
Mesoblast deal inspires Teva to swoop on Cephalon
05 May, 2011 by Tim DeanTeva has outbid Valeant in its offer to buy Cephalon, citing interest in Mesoblast's stem cell therapies.
iCeutica acquired by US pharma
28 April, 2011 by Tim DeanPerth-based iCeutica has been bought up by US pharma company Iroko for a sum reportedly ten times its 2005 valuation.
Feature: Strengthening plant defensins
19 April, 2011 by Graeme O'NeillLa Trobe University’s Marilyn Anderson is developing techniques to boost the natural defences of plants to disease.
Feature: Biodefender
15 April, 2011 by Graeme O'NeillCSIRO Plant Industry vine disease expert, Dr Ian Dry, is strengthening our defences against fungal and insect attacks against crops.
LCT stock up 20% after Japan deal
12 April, 2011 by Staff WritersLiving Cell Technologies (ASX:LCT) has entered into an agreement with Japanese biopharma company, Otsuka Pharmaceutical Factory worth $3 million.
Sirtex sees sales of SIR-Spheres ascend
11 April, 2011 by Staff WritersSirtex (ASX:SRX) shares are up 2.5% after the company reported a 21% increase in dose sales of its liver cancer treatment, SIR-Spheres.
Qiagen makes a grab for Cellestis
04 April, 2011 by Tim DeanCellestis board gives tick of approval to the deal which values the tuberculosis diagnostic company at $341.3 million.
Feature: Shortening the odds in drug design
01 April, 2011 by Fiona WylieFinding just the ideal molecule with just the right binding properties from countless contenders is a daunting challenge for drug design.
Feature: Making drug resistance futile
01 April, 2011 by Fiona WylieMartin Scanlon and his team are using the new fragment-based drug design to combat drug resistance.
Positive trial results for anti-anxiety drug give Bionomics a stock bump
30 March, 2011 by Staff WritersPositive Phase Ib clinical trials of Bionomics’ (ASX:BNO) anti-anxiety drug, BNC210, has seen the stock jump by over 10%.
